Skip to main content
. 2020 Mar 10;14:1057–1081. doi: 10.2147/DDDT.S237252

Table 3.

The Efficacy Scores of Compounds 178258

Compounds % F.F. P.S. % F.F.ave P.S.ave Efficacy Scores Compounds % F.F. P.S. % F.F.ave P.S.ave Efficacy Scores
183 2.5 1.43 0.789 223 4% 1.56 17.0 0.94 0.538
184 1% 1.67 224 2% 1.39
185 225 5% 1.29
186 3% 1.73 226 4% 1.30
187 3% 1.69 227 10% 1.02
188 228
189 3% 0.62 229 24% 0.05
190 230
191 231
192 232 70%
193 1% 1.01 1.3 1.27 0.748 233 9% 1.40 18.6 0.63 0.443
194 0% 1.70 234 8% 1.09
195 1% 1.40 235 8% 0.95
196 1% 1.46 236 12% 0.85
197 0% 1.73 237 13% 0.68
198 238 25% 1.21
199 1% 1.57 239 29%
200 240 34%
201 241 11% 0.16
202 5% 0.05 242 37%
203 2% 1.14 8.2 1.40 0.734 243 25.0 0.65 0.413
204 2% 1.48 244 9% 1.48
205 1% 1.56 245 10% 1.13
206 2% 1.56 246 36%
207 2% 1.39 247 45%
208 3% 1.58 248
209 2% 1.88 249
210 3% 1.82 250
211 64% 251
212 1% 1.62 252
213 3.0 1.16 0.697 253 21% 1.33
214 3% 0.94 254 53%
215 2% 0.87 255 53%
216 3% 1.70 256 49%
217 4% 1.11 257 45%
218 258 27%
219 259 54%
220 260 50%
221 261 11% 0.49
222 262 83%

Notes: Efficacy scores are calculated from % F.F.ave and P.S.ave. Compounds with % F.F. values of <25% fibril formation are included in the plasma selectivity assay as the P.S. values are lower than those of their parent compound 182 (% F.F. values of 26%). Higher efficacy scores correspond to more potent and selective inhibitors.